Диссертация (1140950), страница 24
Текст из файла (страница 24)
№ 11 (112). C. 1644–1654.50. Girardi G. Guilty As Charged : All Available Evidence ImplicatesComplement ’ s Role in Fetal Demise // AJRI. 2008. (59). C. 183–192.51. Goodship T.H.J. [и др.]. Atypical hemolytic uremic syndrome and C3glomerulopathy: conclusions from a “ Kidney Disease: Improving GlobalOutcomes ” (KDIGO) Controversies Conference C.
1–13.52. Hakobyan S. [и др.]. Measurement of Factor H Variants in PlasmaUsingVariant-SpecificMonoclonalAntibodies :ApplicationtoAssessing Risk of Age-Related Macular Degeneration AND // IOVS.2008. № 5 (49). C. 1983–1990.53. Heinen S. [и др.]. Factor H – related protein 1 ( CFHR-1 ) inhibitscomplement C5 convertase activity and terminal complex formation2017. № 12 (114). C. 2439–2448.54. Hellwage J., Jokiranta S., Koistinen V.
Functional properties ofcomplement factor H- related proteins FHR-3 and FHR-4 : Binding to theC3d region of C3b and ... Functional properties of complement factor Hrelated proteins FHR-3 and FHR-4 : binding to the C3d region of C3b anddi ¡ erential re // FEBS Letters. 2000. № 1999 (462). C. 345–352.55. Hofer J. [и др.].
Extra-Renal Manifestations of ComplementMediated Thrombotic Microangiopathies // Frontiers in Pediatrics. 2014.(2). C. 97.56. Jokiranta S. HUS and atypical HUS // Blood. 2017. № 21 (129). C.1442847–2856.57. Jorge E. De [и др.]. Mutations in complement factor B are associatedwith atypical hemolytic uremic syndrome // Molecular Immunology.2007. № 1–3 (44). C. 178–9.58. Jozsi M., Zipfel P.F. Factor H family proteins and human diseases //Trends in Immunology.
2008. № July (8). C. 380–7.59. K.Singer F.P.B. and S.A.W. Thrombotic thrombocytopenic purpura :hemorrhagic diathesis with generalized platelet thrombosis. // Blood.1947. (2). C. 542–554.60. Kang D.., Anderson S., Kim Y.. Impaired angiogenesis in the agingkidney: Vascular endothelial growthfactor and thrombospondin-1 in renaldisease. // Am J Kidney Dis. 2001. (37). C. 601–611.61. Kaplan B., Chesney R., Drummond K. Hemolytic uremic syndromein families.
// N Engl J Med. 1975. (292). C. 1090–3.62. Karmali M.A., Steele B.T. P.M. Sporadic cases of hemolytic uremicsyndrome associated with fatcal cytotoxin and cytotoxin-producingEscherichia coli in stools. // Lancet 1983;1:619-620. 1983. (1). C. 619–620.63. Kavanagh D. [и др.]. Screening for Complemet SystemAbnormalities in Patients with Atypical Hemolytic Uremic Syndrome //Clin JAm Soc Nephrol. 2007. № 3 (2). C. 591–6.64. Kerr H., Richards A. Complement-mediated injury and protection ofendothelium: Lessons from atypical haemolytic uraemic syndrome //Immunobiology.
2012. № 2 (217). C. 195–203.65. Kitchens C.S. Thrombotic storm: when thrombosis begetsthrombosis. // Am J Med. 1998. (104). C. 381–385.66. Kitchens C.S. [и др.]. Thrombotic Storm Revisited : PreliminaryDiagnostic Criteria Suggested by the Thrombotic Storm Study // AJM.2011. № 4 (124). C. 290–296.14567. Lachmann P.
Preparing serum for functional complement assays //Journal of Immunological Methods. 2010. № 1–2 (352). C. 195–197.68. Larakeb A. [и др.]. Ocular involvement in hemolytic uremicsyndromeduetofactorHdeficiency—aretheretherapeuticconsequences? // Pediatr Nephrol. 2007. № 11 (22). C. 1967–70.69. Legendre C.M. [и др.]. Terminal complement inhibitor eculizumab inatypical hemolytic-uremic syndrome // N Engl J Med. 2013. № 23 (368).C.
2169–2181.70. Liszewski K., Liszewski M.K., Atkinson J.P. Complement regulatorCD46 : genetic variants and disease associations Complement regulatorCD46 : genetic variants and disease associations // Human Genomics.2015. № June.71. Loirat C., Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome// Orphanet J Rare Dis. 2011. (6).72. M. Furlan, R. Robles M.G. et al. Von Willebrand factor–cleavingprotease in thrombotic thrombocytopenic purpura and the hemolytic–uremic syndrome.
// NEJM. 1998. (339). C. 1578–84.73. Maga T.K., Nishimura C.J., Weaver A.E. Mutations in AlternativePathway Complement Proteins in American Patients with AtypicalHemolytic Uremic Syndrome Communicated by John McVey // Mutationin Brief. 2010. № March (1460). C. 1445–1460.74. Marco-hernández J. [и др.]. Thrombotic Microangiopathy : Always aChallenging Diagnosis 2016. № july (18). C. 4–5.75. Markiewski M.M. [и др.].
Complement and coagulation : Strangers orpartners in crime ? Complement and coagulation : strangers or partners incrime ? 2007. № 4 (28). C. 184–192.76. Martins P.V. [и др.]. Defining the genetics of thromboticmicroangiopathies // Transfusion and Apheresis Science. 2016. № May.77. Mayilyan K.R. Complement genetics, deficiencies, and disease146associations // Protein & cell.
2012. (3).78. Mcrae J.L. [и др.]. Human Factor H-Related Protein 5 Has CofactorActivity, Inhibits C3 Convertase Activity, Binds Heparin and C-ReactiveProtein, and Associates with Lipoprotein // The Journal of Immunology.2005. (174). C. 6250–6256.79. Melis J. [и др.]. Complement in therapy and disease. // Mol Immunol.2015. № 2 (67). C. 117–30.80. Meri S. Loss of Self-Control in the Complement System and InnateAutoreactivity // Annals of the New York Academy of Sciences. 2007.
№1 (1109). C. 93–105.81. Meri S. Complement activation in diseases presenting withthrombotic microangiopathy // Eur J Intern Med. 2013. № 6 (24). C. 496–502.82. Meroni P.L. [и др.]. Updating on the pathogenic mechanisms 5 of theantiphos-pholipid antibodies-associated pregnancy loss // Clin RevAllergy Immunol.
2008. (34).83. Meroni P.L., Raschi E. C.G. Endothelial activation by aPL : apotential pathogenetic mechanism for the clinical manifestation of thesyndrome // J Autoimmun. 2000. (15). C. 237–240.84. Mieke D., Noris M., Astrid D.V. Thrombomodulin Mutations inAtypical Hemolytic–Uremic Syndrome // New England Journal ofMedicine. 2009. № 4 (361). C. 345–357.85. Miyakis S. [и др.]. International consensus statement on an update ofthe classification criteria for definite antiphospholipid syndrome (APS) //J Thromb Haemost. 2006. (4).86. Moake JL, Byrnes JJ, Troll JH et al Abnormal VIII: von Willebrandfactor patterns in the plasma of patients with the hemolytic-uremicsyndrome // Blood. 1984.
(64). C. 592–8.87. Moake JL, Rudy CK, Troll JH et al. Unusually large plasma factor147VIII:von Willebrand factor multimers in chronic relapsing thromboticthrombocytopenic purpura. // N Engl J Med 1982;307:1432-5. 1982.(307). C. 1432–5.88. Moore I. [и др.]. Association of factor H autoantibodies withdeletions of CFHR1 , CFHR3 , CFHR4 , and with mutations in CFH ,CFI , CD46 , and C3 ...
atypical hemolytic uremic syndrome // Blood.2010. № 2 (115). C. 379–387.89. Morigi M. [и др.]. Alternative Pathway Activation of Complement byShiga Toxin Promotes Exuberant C3a Formation That TriggersMicrovascular Thrombosis 2017.90. Moschcowitz E. An acute febrile pleichromic anaemia with hyalinethrombosis of the terminal arterioles and capillaries // Archives ofInternal Medicine. 1925. (36).
C. 89–93.91. Nangaku M., Shankland S.J., Couser W.G. Cellular Response toInjury in Membranous Nephropathy 2005. C. 1195–1204.92. Neuhaus T.J., Calonder S., Leumann E.P. Heterogeneity of atypicalhaemolytic uraemic syndromes // Archives of Disease in Childhood.1997. № 6 (76). C. 518 LP-521.93. Neumann H P H , Salzmann M, B Bohnert-Iwan B M.T. et al.Haemolytic uraemic syndrome and mutations of the factor H gene: Aregistry-based study of German speaking countries 2003. (40).
C. 676–681.94. Noone D. [и др.]. Spectrum of Complement-Mediated ThromboticMicroangiopathies : Pathogenetic Insights Identifying Novel ... Spectrumof Complement-Mediated Thrombotic Microangiopathies : PathogeneticInsights Identifying Novel Treatment Approaches 2014. № June.95. Noris M. [и др.]. Relative role of genetic complement abnormalitiesin sporadic and familial aHUS and their impact on clinical phenotype //CJASN. 2010. (5).14896. Noris M. [и др.]. Relative role of genetic complement abnormalitiesin sporadic and familial aHUS and their impact on clinical phenotype //Clinical Journal of the American Society of Nephrology.
2010. № 10 (5).C. 1844–1859.97. Noris M., Mescia F., Remuzzi G. STEC-HUS, atypical HUS and TTPare all diseases of complement activation // Nat Rev Nephrol. 2012. № 8(11). C. 622–633.98. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome // N EnglJ Med. 2009. (361). C. 1676–1687.99.
Noris M., Remuzzi G. Cardiovascular complications in atypicalhaemolytic uraemic syndrome 2014. (10). C. 174.100. Noris M., Remuzzi G. Glomerular Diseases Dependent onComplementSyndrome,Activation,IncludingMembranoproliferativeAtypicalHemolyticGlomerulonephritis,UremicandC3Glomerulopathy: Core Curriculum 2015 // American Journal of KidneyDiseases. 2015. № 2 (66). C. 359–375.101. Orth D., Würzner R. Complement in Typical Hemolytic UremicSyndrome // Semin Thromb Hemost.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
